help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiedemann, E.
Right arrow Articles by Frantz, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiedemann, E.
Right arrow Articles by Frantz, A. G.

Journal of Clinical Endocrinology & Metabolism, Vol 42, 942-952, Copyright © 1976 by Endocrine Society


ARTICLES

Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man

E Wiedemann, E Schwartz and AG Frantz

Estrogen (E) reduces bioassayable GH-dependent serum somatomedin (SM) activity in acromegalics without affecting plasma growth hormone (GH) levels and inhibits the rise of SM activity normally produced by GH administration in GH-deficient subjects. We have now investigated the effect of E administration on serum SM activity and on plasma GH and prolactin (PRL) in 6 adult male subjects without pituitary pathology. Chronic E administration (ethinyl estradiol 0.5 mg/day for 7 to 70 days) reduced serum SM activity by 40 to 62% in each of 4 subjects (P less than 0.02 to less than 0.001). In 3 of the subjects, basal GH levels increased by 75 to 300% (P less than 0.05 to less than 0.001) and basal PRL levels increased by 90 to 200% (P less than 0.01 to less than 0.001). While iv administration of normal saline did not significantly affect either SM or GH, iv administration of E (bolus injection of 25 mg conjugated estrogens, USP) to 5 subjects resulted in: a) a 46 to 80% decrease in serum SM activity in all subjects, proceeding with an apparent half-life of 2 hours, becoming significant (P less than 0.05) at 2 hours (1 subject) to 3 hours (4 subjects), maximal at 6 hours, and persisting for 12 to 24 hours; b) GH elevation to 3 to 16 times baseline level (P less than 0.01) at 2 to 3 hours in 4 subjects; and c) no significant change of PRL levels in any subject. The mean GH response to iv E was maximal at a time (2 hours) when the mean SM activity had decreased only 20% and subsided well before the nadir of SM activity. The one patient without GH response to chronic or acute E administration may have been affected by absorption of triamcinolone being applied topically during the study. These results demonstrate that in males with normal pituitary function, E reduces serum SM activity, enhances basal GH and PRL secretion, and, upon iv injection, stimulates acute GH release. Although opposite chronic E effects upon GH and SM activity support a putative negative SM-GH feed- back mechanism, iv E administration apparently provokes acute GH release by a different mechanism. The half-life of serum SM activity in the human is probably much shorter than previously estimated.


This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
R. P A Rooman, L. O. De Beeck, M. Martin, J. van Doorn, S. Mohan, and M. V L Du Caju
Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature
Eur. J. Endocrinol., April 1, 2005; 152(4): 597 - 604.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho
Estrogen Regulation of Growth Hormone Action
Endocr. Rev., October 1, 2004; 25(5): 693 - 721.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
J. M. Fitts, R. M. Klein, and C. A. Powers
Comparison of Tamoxifen and Testosterone Propionate in Male Rats: Differential Prevention of Orchidectomy Effects on Sex Organs, Bone Mass, Growth, and the Growth Hormone-IGF-I Axis
J Androl, July 1, 2004; 25(4): 523 - 534.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Decker, C.-J. Partsch, and W. G. Sippell
Combined Treatment with Testosterone (T) and Ethinylestradiol (EE2) in Constitutionally Tall Boys: Is Treatment with T Plus EE2 More Effective in Reducing Final Height in Tall Boys than T Alone?
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1634 - 1639.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Gentili, T. Mulligan, M. Godschalk, J. Clore, J. Patrie, A. Iranmanesh, and J. D. Veldhuis
Unequal Impact of Short-Term Testosterone Repletion on the Somatotropic Axis of Young and Older Men
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 825 - 834.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen
Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids
Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Maccario, G. Aimaretti, G. Corneli, C. Gauna, S. Grottoli, M. Bidlingmaier, C. J. Strasburger, C. Dieguez, F. F. Casanueva, and E. Ghigo
Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans
Am J Physiol Endocrinol Metab, August 1, 2000; 279(2): E411 - E416.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. L. Asa and S. Ezzat
The Cytogenesis and Pathogenesis of Pituitary Adenomas
Endocr. Rev., December 1, 1998; 19(6): 798 - 827.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Parini, B. Angelin, and M. Rudling
Importance of Estrogen Receptors in Hepatic LDL Receptor Regulation
Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1800 - 1805.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
C. H. Gravholt, R. W. Naeraa, S. Fisker, and J. S. Christiansen
Body Composition and Physical Fitness Are Major Determinants of the Growth Hormone-Insulin-Like Growth Factor Axis Aberrations in Adult Turner's Syndrome, with Important Modulations by Treatment with 17{beta}-Estradiol
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2570 - 2577.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. Hornum, D. M. Cooper, J. A. Brasel, A. Bueno, and K. E. Sietsema
Exercise-induced changes in circulating growth factors with cyclic variation in plasma estradiol in women
J Appl Physiol, June 1, 1997; 82(6): 1946 - 1951.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
F. I. Sharara and L. C. Giudice
Role of Gorwth Hormone in Ovarian Physiology and Onest of Puberty
Reproductive Sciences, January 1, 1997; 4(1): 2 - 7.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1976 by The Endocrine Society